drugset / Trial / NCT03296553

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

NCT03296553

RandomizedParallel-groupOpen-labelTreatment

Summary

Kaposi sarcoma (KS) has an unpredictable course, patients with disseminated KS starting combined Antiretroviral Therapy can develop Immune Reconstitution Syndrome (IRIS), with a severe clinical presentation and high mortality (severe-IRIS-KS). The objective of this study is to evaluate the presence of Severe IRIS-KS and it´s attributable mortality in patients with AIDS and disseminated KS with the use of valganciclovir prior to the initiation of cART compared with the standard management of immediate cART initiation.

Timeline

Start
2015-10-01
Primary completion
2019-08-26
Completion
2019-08-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule 900 mg Oral